The right drug, to the right patient, at the right price




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: The right drug, to the right patient, at the right price
Released on: November 04, 2015. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Immune Pharmaceuticals Inc.
  • Summary
  • Transcript
  • Participants
  • Company
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) is developing precision immunotherapies for inflammatory diseases and cancer. Immune’s core programme includes Bertilimumab (currently in phase II in ulcerative colitis, Bullous Pemphigold and Crohn’s disease), Cyclosporine A (for psoriasis and atopic dermatitis), and NanomAbs (an antibody drug conjugate platform for targeted delivery of chemotherapeutics). Daniel Teper, CEO to Immune Pharma, talks to Fintan Walton about Immune’s current portfolio and future partnering opportunities.
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) is developing precision immunotherapies for inflammatory diseases and cancer. Immune’s core programme includes Bertilimumab (currently in phase II in ulcerative colitis, Bullous Pemphigold and Crohn’s disease), Cyclosporine A (for psoriasis and atopic dermatitis), and NanomAbs (an antibody drug conjugate platform for targeted delivery of chemotherapeutics). Daniel Teper, CEO to Immune Pharma, talks to Fintan Walton about Immune’s current portfolio and future partnering opportunities.
Dr. Daniel Teper is the founder and CEO of IMMUNE Pharmaceuticals. Dr. Teper was the Managing Director for North America at Bionest Partners, a global Strategy Consulting firm advising pharmaceutical and public biotechnology companies and previously a New York based Partner at ISO Healthcare Consulting (now part of Monitor Group). Daniel started his career at Sandoz (now Novartis) Global Headquarters in Basel and then in the United States where he had growing responsibilities in sales, marketing and new product development. He held senior executive positions in Europe, first at GSK as Head of Commercial Operations for Glaxo France and then as President and Chief Operating Officer of Laboratoires Delagrange through the acquisition by Synthelabo (now part of Sanofi). He then became President at Global EURO RSCG Healthcare Worldwide, a leading marketing and communication group, where he help launch multiple industry blockbusters. Daniel was a cofounder of Novagali (NYSE Euronext: NOVA), which was recently acquired by Japan’s Santen. Dr. Teper holds a Doctor of Pharmacy degree (PharmD) from Paris XI University and an MBA from INSEAD.
Immune Pharma
Immune Pharmaceuticals is on a mission to improve patients' lives through targeted medicine. Our work is focused on addressing significant unmet medical needs in the treatment of cancer and inflammatory diseases through the development of the next generation of monoclonal antibodies and nano therapeutics.